Annonaceae acetogenins: A potential treatment for gynecological and breast cancer

Diego A Bravo-Alfaro1, Efigenia Montalvo-González2, J Martin Zapien-Macias3

  • 1Tecnologico de Monterrey, Institute of Advanced Materials for Sustainable Manufacturing, Epigmenio González 500 Fracc. San Pablo, Querétaro, Qro 76130, Mexico.

Fitoterapia
|August 15, 2024
PubMed

Insights

Acetogenins from the Annonaceae family show promising anticancer potential against breast and gynecological cancers. This review details their origin, structure, and antitumor activities, suggesting future therapeutic applications.

Area of Science:

  • Natural Product Chemistry
  • Oncology
  • Pharmacology

Background:

  • Breast and gynecological cancers pose significant health challenges with increasing incidence and survival concerns.
  • Natural compounds are being explored as alternative cancer treatments.
  • Acetogenins, plant metabolites from Annonaceae, exhibit documented anticancer activity in vitro and in vivo.

Purpose of the Study:

  • To review the origin, structure, and antineoplastic activities of Annonaceae Acetogenins against breast and gynecological cancers.
  • To systematically summarize the anticancer mechanisms of Acetogenins.
  • To provide references for future Acetogenin-based therapies combined with nanotechnologies.

Main Methods:

  • Literature review of studies on Acetogenins from Annonaceae.
  • Analysis of in vitro and in vivo antineoplastic activities.
  • Systematic summary of reported mechanisms of action.

Main Results:

  • Acetogenins demonstrate selective cellular inhibition at low concentrations.
  • Promising antitumor capacity reported across various cancer cell lines.
  • Evidence supports Acetogenins' potential as anticancer agents.

Conclusions:

  • Acetogenins are a promising class of natural compounds for treating breast and gynecological cancers.
  • Further research into Acetogenins' mechanisms and combination therapies is warranted.
  • Future therapies may integrate Acetogenins with nanotechnologies for enhanced efficacy.

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
154
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
6.1K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
181